Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.00 (0.00%)
Bid:
1.70
Ask:
2.16
Spread: 0.46 (27.059%)
Market Cap: £5.96m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

License Agreement

9 Apr 2010 07:00

RNS Number : 9292J
Proteome Sciences PLC
09 April 2010
 



 

 

Proteome Sciences plc

ProteoPrep License agreement with Sigma-Aldrich

 

 

9th April, 2010 Proteome Sciences plc ("Proteome Sciences") is pleased to announce that it has entered into a non-exclusive license agreement with Sigma-Aldrich Corporation ("Sigma") under which Sigma will be able to continue selling products under Proteome's registered trademark ProteoPrep® in Europe, Japan and Australia. Sigma is the world's largest supplier of research biochemicals and organic chemicals with over one million customers.

 

There are currently eleven ProteoPrep® kits available from Sigma and the license will also include all future products sold under the ProteoPrep® trademark that contain chemicals and reagents for the disruption of cells, tissues or other biological material and the extraction of biological molecules like proteins, lipids and carbohydrates. It also covers methods and processes relating to assays for the diagnosis of diseases and chemical markers determining targets for drugs and for determining proteins and peptides by disruption of cells, tissues or other biological material. The license provides Proteome with a signature fee and royalties on all ProteoPrep® sales in the jurisdictions listed above.

 

Commenting on the license Christopher Pearce, Chief Executive of Proteome Sciences said:

 

"We are delighted to have concluded the license with Sigma-Aldrich Corporation for the ProteoPrep® trademark and look forward to receiving this new stream of revenue from royalties generated by their successful and expanding range of ProteoPrep® products."

 

 

 

- End -

 

 

For further information please contact:

 

Proteome Sciences plc

www.proteomics.com Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com 

James Malthouse, Finance Director james.malthouse@proteomics.com 

Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com 

 

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: +44 (0)20 3205 7500

 

Public Relations

IKON Associates Redleaf Communications Limited

Adrian Shaw Anna Dunkin/Lucy Salaman

Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700

Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com 

Email: adrian@ikonassociates.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRLLFLRSDITIII
Date   Source Headline
4th Apr 20174:35 pmRNSPrice Monitoring Extension
4th Apr 20177:00 amRNSOption Awards
3rd Apr 20177:00 amRNSAppointment of Richard Dennis as CCO
31st Mar 20174:45 pmRNSBlock Admission Return
28th Mar 20177:00 amRNSPreliminary Results
9th Feb 20177:00 amRNSTrading Update & Notice of Results
4th Jan 20174:36 pmRNSHoldings in Company / PDMR Shareholding
3rd Jan 20171:34 pmRNSHoldings in Company / PDMR Shareholding
30th Dec 201611:42 amRNSHolding(s) in Company
19th Dec 20167:00 amRNSLaunch of new website
16th Dec 20169:28 amRNSHolding(s) in Company
29th Nov 201610:43 amRNSResult of GM and Completion of Placing
18th Nov 20169:46 amRNSHolding(s) in Company
8th Nov 201610:12 amRNSHolding(s) in Company
4th Nov 20163:52 pmRNSDirector/PDMR Shareholding & Total Voting Rights
2nd Nov 20164:35 pmRNSPrice Monitoring Extension
31st Oct 20167:00 amRNSPlacing and Subscription to raise £3.3 million
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
4th Oct 20164:35 pmRNSPrice Monitoring Extension
3rd Oct 20167:00 amRNSBlock Admission return
29th Sep 20167:00 amRNSHolding(s) in Company
22nd Sep 20167:00 amRNSPublication: Journal of Alzheimer's disease
15th Sep 20167:00 amRNSHalf-year Report
28th Jul 20167:00 amRNSTrading Update and Notice of Results
24th Jun 201612:30 pmRNSAGM Statement and Result of AGM
1st Jun 20167:00 amRNSAppointment of CEO
31st May 20163:20 pmRNSPublication of Annual Report
18th May 20167:01 amRNSCEO Appointment
18th May 20167:00 amRNSPreliminary Results
5th Apr 20167:00 amRNSDeep Protein Profiling Key re. Cancer Treatment
1st Apr 20168:04 amRNSBlock Admission return
29th Feb 20167:00 amRNSTrading Update
5th Jan 20169:43 amRNSDirector Dealing
14th Dec 20154:02 pmRNSDirector Dealing
14th Dec 20159:36 amRNSHolding(s) in Company
5th Nov 20157:00 amRNSClinical Trial Results for CK1d
1st Oct 20157:00 amRNSBlock Admission return
30th Sep 20157:00 amRNSUnaudited Interim Results
4th Sep 20157:00 amRNSChange of Adviser
17th Jul 201512:01 pmRNSAGM Statement
13th Jul 20152:48 pmRNSHolding(s) in Company
3rd Jul 20155:03 pmRNSHolding(s) in Company
23rd Jun 20157:05 amRNSPublication of Annual Report
23rd Jun 20157:00 amRNSPlacing to raise £2.5 million
29th May 20157:00 amRNSPreliminary results
30th Mar 20154:21 pmRNSBlocklisting Interim Review
9th Mar 20157:00 amRNSTrading Statement
1st Dec 20143:15 pmRNSDirectorate Change
28th Nov 20147:00 amRNSSysQuant - Update/Contract Awards

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.